

From Pipeline to Patient: Delivering on the Promise of Precision Oncology and Beyond

Wednesday, 1 October 2025 | 15:30–17:30 JST

Venue: Pacifico Yokohama North, Yokohama, Kanagawa, Japan
icgc-argo-japan2025.com

The **ICPC-ICGC ARGO Stakeholder Forum in Yokohama** takes place immediately after the **United Nations General Assembly High-Level Week in New York**, where Heads of State, ministers, multilateral institutions, and global civil society came together to confront the growing burden of cancer and other non-communicable diseases.

During the New York sessions, a broad coalition of governments, UN agencies, development banks, industry, academia, and patient organisations endorsed the **Consensus Framework: The Last Mile Action Agenda**, which set out three shared priorities:

1. Equitable early detection – embedding genomics, AI, and innovative screening into healthcare systems.
2. Strengthening partnerships and capacity – empowering countries through education, workforce, and collaboration.
3. Mobilising sustainable financing – developing innovative models for reimbursement, access, and health system resilience.

The political discussions in New York highlighted not only the urgency of cancer and NCD action but also the importance of mobilising institutional support across the World Bank, IMF, WHO, and regional agencies, alongside the critical voices of patient groups and scientific leaders. Stakeholders emphasised that innovation without delivery risks deepening inequities, and that cross-sector cooperation is essential to close the gap.

The Yokohama Forum therefore serves as the next step in this global arc: moving from high-level political consensus to practical strategies for precision oncology and genomics delivery. It also recognises that lessons from oncology – in areas such as trial design, bioinformatics, and early detection – can inform broader innovation for health systems and other diseases.

By convening leading clinicians, scientists, policymakers, and patient advocates, the Forum will focus on how to reach the *last mile*: ensuring that discoveries move from laboratories and political declarations into real-world patient care, accessible and equitable worldwide.

Co-funded by the European Union, the Summit aligns with the broader ambition of Vision Europe 2030 to advance equitable access to innovation, strengthen resilient cancer systems, and deliver meaningful improvements for patients worldwide.

Welcome & Context Setting (15:30–15:45, 15 minutes)



Co-funded by
the European Union

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them.

Speakers (3 minutes each):

- **Andrew Biankin**, Professor of Surgery & Director, Wolfson Wohl Cancer Research Centre, University of Glasgow, UK – [Angle: precision oncology & international cancer genomics leadership \(CONFIRMED\)](#)
- **Takayuki Yoshino**, Deputy Director, National Cancer Center Hospital East, Japan – [Angle: gastrointestinal cancers & clinical trials](#)
- **Denis Horgan**, Secretary General, International Cancer Patient Coalition (ICPC) – [Angle: global patient and policy advocacy](#)

Remaining time (6 minutes): Opening discussion & interactive poll.

Debate 1 – Is Genomics Reaching the Patient Bedside? (15:45–16:15, 30 minutes)

Narrative: Scientific advances in genomics and biomarkers have created new opportunities in cancer, rare diseases, and chronic conditions. Yet, clinical integration remains slow and unequal. This session explores barriers and enablers to bring discovery to bedside care, aligned with the *Last Mile* pillar on early detection and equitable access.

Moderators:

- **Denis Horgan**, Secretary General, ICPC
- **Rita Lawlor**, Director, ARC-Net Research Centre, University of Verona, Italy – [Angle: biobanking, colorectal & pancreatic cancer \(CONFIRMED\)](#)

Speakers (3 minutes each):

- **Masaki Ishida**, Professor, Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Japan – [Angle: lung cancer & respiratory diseases](#)
- **Heidi Rehm**, Chief Genomics Officer, Massachusetts General Hospital; Medical & Clinical Director, Broad Institute of MIT and Harvard, USA – [Angle: clinical genomics & rare disease standards](#)
- **Sylvia Plevritis**, Chair, Department of Biomedical Data Science, Stanford University, USA – [Angle: AI modeling & biomedical data science](#)
- **Wai Poon**, Clinical Oncologist, Department of Clinical Oncology, The Chinese University of Hong Kong – [Angle: precision oncology & targeted therapies](#)

Remaining time (18 minutes): Moderated panel discussion.

Debate 2 – Stratified Screening as the New Frontline (16:15–16:45, 30 minutes)

Narrative: Screening programs are shifting from broad, population-based models to precision, risk-stratified approaches informed by genomics and AI. This session focuses on how health systems can adapt infrastructure, workforce, and policy to make this shift, reflecting the *Last Mile* pillar on partnerships and capacity building.



Co-funded by
the European Union

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them.

Moderators:

- **Denis Horgan**, Secretary General, ICPC
- **Amber Johns**, Senior Policy Manager, Garvan Institute of Medical Research, Australia – Angle: policy, regulation & genomics governance

Speakers (3 minutes each):

- **Philip Beer**, Honorary Fellow, University of York, UK – Angle: biomarker-driven screening & genomics
- **Jeongbin Park**, Department of Internal Medicine, Pusan National University, South Korea – Angle: oncology & population health
- **Bayarbat Tsevegjav**, Center for Cancer Immunotherapy and Immunobiology, Kyoto University, Japan – Angle: cancer immunotherapy & immunobiology
- **Jessica Nelson**, Scientist, Canada's Michael Smith Genome Sciences Centre, BC Cancer, Canada – Angle: genomics data & precision medicine
- **Melanie Courtot**, Lead, Data Coordination & Standards, Ontario Institute for Cancer Research (OICR), Canada – Angle: bioinformatics & health data standards (CONFIRMED)

Remaining time (15 minutes): Moderated discussion.

Debate 3 – Trials and Real-World Data: A Genomic Inclusion Test (16:45–17:10, 25 minutes)

Narrative: Adaptive trial models, synthetic control arms, and real-world data can expand access and efficiency in precision medicine. This session will explore frameworks to ensure inclusivity, efficiency, and sustainability, aligned with the *Last Mile* pillar on sustainable financing.

Moderators:

- **Denis Horgan**, Secretary General, ICPC
- **Woong-Yang Park**, Director, Samsung Genome Institute; Professor, Seoul National University, South Korea – Angle: cancer genomics, immunology & translational medicine (CONFIRMED)

Speakers (3 minutes each):

- **Steven Jones**, Co-Director, Canada's Michael Smith Genome Sciences Centre, BC Cancer, Canada – Angle: population-scale genomics & data analysis (CONFIRMED)
- **Daniel Renouf**, Co-Director, Pancreas Centre BC; BC Cancer, Canada – Angle: pancreatic cancer & personalized therapy
- **Quaid Morris**, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, USA – Angle: AI & computational genomics



Co-funded by
the European Union

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them.

- **Jianmin Wu**, *Peking University Cancer Hospital & Institute, China* – Angle: oncology & clinical trials in Asia
- **Edmund Su**, *Scientist, Ontario Institute for Cancer Research (OICR), Canada* – Angle: bioinformatics & clinical data integration

Remaining time (10 minutes): Panel discussion.

Closing Discussion & Commitments (17:10–17:20, 10 minutes)

Narrative: This session synthesises outcomes and defines practical next steps, mapping them onto the *Last Mile Consensus Framework*. The goal is to ensure innovations move from political agreement to real patient benefit.

Speakers (3 minutes each):

- **Aldo Scarpa**, *Director, RC-Net Research Centre, University of Verona, Italy* – Angle: cancer pathology & genomics (CONFIRMED)
- **James Topham**, *Co-Director, Pancreas Centre BC, Canada* – Angle: pancreatic cancer clinical translation
- **Denis Horgan**, *Secretary General, ICPC* – Angle: connecting patients, policy & implementation

Remaining time (1 minute): Rapporteur wrap-up.

Final Synthesis & Next Steps (17:20–17:30, 10 minutes)

Narrative: Short reflections from key leaders on lessons from the UNGA meetings and Kyoto, and how to sustain momentum toward “last mile” delivery.

Speakers (3 minutes each):

- **Andrew Biankin**, *University of Glasgow, UK*
- **Takayuki Yoshino**, *National Cancer Center Hospital East, Japan*
- **Denis Horgan**, *Secretary General, ICPC*

Remaining time (1 minute): Open reflection and closing.



Co-funded by
the European Union

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them.